Status:
WITHDRAWN
Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Lung Cancer (NSCLC)
Neoadjuvant Immunotherapy
Eligibility:
All Genders
18-85 years
Brief Summary
The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically rese...
Eligibility Criteria
Inclusion
- (1) aged 18 years or older; (2) pathological diagnosis of non-small cell lung cancer; (3) lesions resectable by surgery; (4) no EGFR mutation or ALK mutation; (5) eligible for indications of neoadjuvant immunotherapy for lung cancer.
- \-
Exclusion
- (1) patients who had used any other antitumor drugs or radiotherapy; (2) comorbidities with other malignant neoplastic diseases or severe cardiovascular diseases; (3) uncontrollable diabetes mellitus or fasting blood glucose level higher than 11 mmol/L on the test day; (4) pregnancy or recent pregnancy plan; (5) distant metastasis.
- \-
Key Trial Info
Start Date :
April 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2027
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06895941
Start Date
April 30 2025
End Date
April 1 2027
Last Update
April 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai East Hospital
Shanghai, Shanghai Municipality, China, 200433
2
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433